Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
作者:Ming He、Wentao Ning、Zhiye Hu、Jian Huang、Chune Dong、Hai-Bing Zhou
DOI:10.1016/j.ejmech.2020.112281
日期:2020.6
dual-targeting drugs has become a new strategy. In this study, we have developed a series of dual-acting agents targeting both estrogen receptor α (ERα) and histone demethylase based on a privileged OBHS pharmacophore scaffold developed previously by our laboratory. These novel OBHS-LSD1i conjugates showed excellent ERα binding affinity and selectivity, and exhibited potent inhibitory activity against lysine
乳腺癌是一种多因素疾病,因此越来越多的药物联合疗法被用于治疗。但是,药物联合治疗存在不可否认的缺点。因此,开发新型的双重靶向药物已经成为一种新的策略。在这项研究中,我们基于实验室先前开发的OBHS药效基团支架,开发了一系列针对雌激素受体α(ERα)和组蛋白脱甲基酶的双作用剂。这些新颖的OBHS-LSD1i共轭物表现出优异的ERα结合亲和力和选择性,并表现出对赖氨酸特异性脱甲基酶1(LSD1)的有效抑制活性。与4-羟基他莫昔芬体外相比,几种缀合物在MCF-7乳腺癌细胞系中显示出更高的抗增殖功效。其中,最佳化合物11g对LSD1和MCF-7细胞表现出有效的抑制活性,IC50值分别为1.55μM和8.79μM。流式细胞术分析11g的凋亡表明这种类型的化合物对MCF-7细胞的影响部分是由诱导凋亡引起的。而且,11g与ERα的分子对接以及LSD1 / CoREST配合物的活性位点为理解这类化合物与靶